Search hospitals > Iowa > Ames
McFarland Clinic PC - Ames
Claim this profileAmes, Iowa 50010
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Stomach Cancer
268 reported clinical trials
3 medical researchers
Summary
McFarland Clinic PC - Ames is a medical facility located in Ames, Iowa. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Stomach Cancer and other specialties. McFarland Clinic PC - Ames is involved with conducting 268 clinical trials across 386 conditions. There are 3 research doctors associated with this hospital, such as Debra M. Prow, Joseph J. Merchant, and Christina Taylor, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Debra M. ProwMcFarland Clinic PC - Ames6 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
125 reported clinical trials
185 drugs studied
Joseph J. MerchantMcFarland Clinic - Ames2 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
100 reported clinical trials
153 drugs studied
Christina Taylor, MDMcFarland Clinic2 years of reported clinical research
Studies Dementia
1 reported clinical trial
1 drug studied
Clinical Trials running at McFarland Clinic PC - Ames
Skin Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Bladder Cancer
Kidney Cancer
Cutaneous Melanoma
Non-Small Cell Lung Cancer
Bladder Carcinoma
Melanoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McFarland Clinic PC - Ames?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.